n- ( 5-indanylsulfonyl ) -n'- ( 4-chlorophenyl ) -urea ( ly186641 ) , a novel anticancer compound , was evaluated against six lines of rhabdomyosarcoma xenografts , each of which was established from tissue biopsies from untreated patients , and additional sublines selected as xenografts for primary resistance to vincristine , melphalan , and ifosfamide .
C0035412
rhabdomyosarcoma
C0042679
vincristine